-
公开(公告)号：US11918596B2
公开(公告)日：2024-03-05
申请号：US17381488
申请日：2021-07-21
发明人： Uli Christian Broedl , Odd-Erik Johansen , Gabriel Woojai Kim , Eric Williams Mayoux , Afshin Salsali , Nima Soleymanlou , Maximilian von Eynatten , Hans-Juergen Woerle , David Z. I. Cherney , Bruce A. Perkins , Andreas Daiber , Thomas Muenzel
IPC分类号： A61K31/7048 , A61K9/20 , A61K9/28 , A61K31/155 , A61K31/522 , A61K31/7034 , A61K45/06
CPC分类号： A61K31/7048 , A61K9/2018 , A61K9/2866 , A61K31/155 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K31/7048 , A61K2300/00 , A61K31/155 , A61K2300/00 , A61K31/522 , A61K2300/00
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
-
公开(公告)号：US20190015437A1
公开(公告)日：2019-01-17
申请号：US15918477
申请日：2018-03-12
发明人： Uli Christian Broedl , Odd-Erik Johansen , Gabriel Woojai Kim , Eric Williams Mayoux , Afshin Salsali , Nima Soleymanlou , Maximilian von Eynatten , Hans-Juergen Woerle , David Z.I. Cherney , Bruce A. Perkins , Andreas Daiber , Thomas Muenzel
IPC分类号： A61K31/7048 , A61K31/522 , A61K31/155 , A61K31/7034 , A61K45/06 , A61K9/28 , A61K9/20
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
-
公开(公告)号：US09949997B2
公开(公告)日：2018-04-24
申请号：US14918713
申请日：2015-10-21
发明人： Uli Christian Broedl , Odd-Erik Johansen , Gabriel Woojai Kim , Eric Williams Mayoux , Afshin Salsali , Nima Soleymanlou , Maximilian von Eynatten , Hans-Juergen Woerle , David Z. I. Cherney , Bruce A. Perkins , Andreas Daiber , Thomas Muenzel
IPC分类号： A61K31/7048 , A61K31/155 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K9/20 , A61K9/28
CPC分类号： A61K31/7048 , A61K9/2018 , A61K9/2866 , A61K31/155 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K2300/00
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
-
公开(公告)号：US11813275B2
公开(公告)日：2023-11-14
申请号：US17381498
申请日：2021-07-21
发明人： Uli Christian Broedl , Odd-Erik Johansen , Gabriel Woojai Kim , Eric Williams Mayoux , Afshin Salsali , Nima Soleymanlou , Maximilian von Eynatten , Hans-Juergen Woerle , David Z.I. Cherney , Bruce A. Perkins , Andreas Daiber , Thomas Muenzel
IPC分类号： A61K31/7048 , A61K9/20 , A61K9/28
CPC分类号： A61K31/7048 , A61K9/2018 , A61K9/2866
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
-
公开(公告)号：US11666590B2
公开(公告)日：2023-06-06
申请号：US17094037
申请日：2020-11-10
发明人： Uli Christian Broedl , Odd-Erik Johansen , Eric Williams Mayoux , Nima Soleymanlou , Maximilian von Eynatten , Hans-Juergen Woerle , David Z.I. Cherney , Bruce A. Perkins
IPC分类号： A61K31/7048 , A61K45/06 , A61K38/28 , A61K9/20 , A61K9/28 , A61K31/155 , A61K31/522
CPC分类号： A61K31/7048 , A61K9/2018 , A61K9/2866 , A61K31/155 , A61K31/522 , A61K38/28 , A61K45/06 , A61K31/155 , A61K2300/00 , A61K31/7048 , A61K2300/00 , A61K38/28 , A61K2300/00 , A61K31/522 , A61K2300/00
摘要： The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
-
-
-
-
搜索结果
5 条记录 (耗时 0.019 秒)
